Acorda Therapeutics, Inc. (ACORQ) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
TWO BLUE HILL PLAZA PEARL RIVER, NY 10965 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 29,979 | 32,468 | 25,270 | 30,255 | 37,536 | 20,696 | |||
| Cash and cash equivalent | 29,979 | 32,468 | 25,270 | 30,255 | 37,536 | 20,696 | |||
| Restricted cash and investments | 381 | 861 | 828 | 6,989 | 6,884 | 13,232 | |||
| Receivables | 17,298 | 11,977 | 13,390 | 9,190 | 13,866 | 14,690 | |||
| Inventory, net of allowances, customer advances and progress billings | 16,155 | 17,942 | 14,797 | 13,465 | 12,752 | 15,252 | |||
| Inventory | 16,155 | 17,942 | 14,797 | 13,465 | 12,752 | 15,252 | |||
| Prepaid expense | 5,211 | 5,042 | 5,480 | 4,125 | 4,312 | 5,111 | |||
| Other current assets | 5,770 | 5,438 | 5,149 | 4,070 | 6,765 | 2,711 | |||
| Total current assets: | 74,794 | 73,728 | 64,914 | 68,094 | 82,115 | 71,692 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 4,221 | 4,496 | 4,765 | 5,029 | 5,287 | 5,541 | |||
| Property, plant and equipment | 2,079 | 2,210 | 2,163 | 2,383 | 2,603 | 2,825 | |||
| Intangible assets, net (including goodwill) | 22,987 | 282,006 | 289,700 | 297,393 | 305,087 | 312,779 | |||
| Intangible assets, net (excluding goodwill) | 22,987 | 282,006 | 289,700 | 297,393 | 305,087 | 312,779 | |||
| Restricted cash and investments | 255 | 255 | 255 | 510 | 255 | 255 | |||
| Other noncurrent assets | 4,189 | 3,649 | 2,899 | 1,497 | 248 | 247 | |||
| Total noncurrent assets: | 33,731 | 292,616 | 299,782 | 306,812 | 313,480 | 321,647 | |||
| TOTAL ASSETS: | 108,525 | 366,344 | 364,696 | 374,906 | 395,595 | 393,339 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 37,683 | 41,674 | 24,997 | 29,871 | 33,489 | 38,210 | |||
| Accounts payable | 13,373 | 12,330 | 3,175 | 2,854 | 9,809 | 11,505 | |||
| Accrued liabilities | 24,310 | 29,344 | 21,822 | 27,017 | 23,680 | 26,705 | |||
| Deferred revenue | 227 | 465 | 548 | 384 | |||||
| Debt | 186,143 | ||||||||
| Business combination, contingent consideration, liability | 2,132 | 2,577 | 3,274 | 3,312 | 2,532 | 2,359 | |||
| Other undisclosed current liabilities | 1,588 | 1,578 | 1,567 | 1,556 | 1,545 | 1,454 | |||
| Total current liabilities: | 227,773 | 46,294 | 30,386 | 34,739 | 37,950 | 42,023 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 181,043 | 176,164 | 171,496 | 167,031 | 192,301 | ||||
| Long-term debt, excluding current maturities | 181,043 | 176,164 | 171,496 | 167,031 | 187,689 | ||||
| Liabilities, other than long-term debt | 38,708 | 80,050 | 90,278 | 91,711 | 96,992 | 83,249 | |||
| Deferred income tax liabilities | 38,544 | 39,556 | 41,805 | 44,202 | 42,228 | ||||
| Other liabilities | 8,174 | 7,815 | 11,732 | 9,363 | 9,781 | 5,780 | |||
| Operating lease, liability | 3,166 | 3,468 | 3,764 | 4,055 | 4,341 | 4,612 | |||
| Business combination, contingent consideration, liability | 27,368 | 30,223 | 35,226 | 36,488 | 38,668 | 35,241 | |||
| Other undisclosed noncurrent liabilities | (315,912) | ||||||||
| Total noncurrent liabilities: | (277,204) | 261,093 | 266,442 | 263,207 | 264,023 | 275,550 | |||
| Total liabilities: | (49,431) | 307,387 | 296,828 | 297,946 | 301,973 | 317,573 | |||
| Equity | |||||||||
| Equity, attributable to parent | (157,956) | 58,957 | 67,868 | 76,960 | 93,622 | 75,766 | |||
| Common stock | 1 | 1 | 1 | 24 | 24 | 24 | |||
| Treasury stock, value | (638) | (638) | (638) | (638) | (638) | (638) | |||
| Additional paid in capital | 1,030,383 | 1,030,243 | 1,030,103 | 1,029,952 | 1,029,881 | 1,029,705 | |||
| Accumulated other comprehensive income | 1,425 | 717 | 880 | 719 | 628 | 2,090 | |||
| Accumulated deficit | (1,189,127) | (971,366) | (962,478) | (953,097) | (936,273) | (955,415) | |||
| Other undisclosed equity | 315,912 | ||||||||
| Total equity: | 157,956 | 58,957 | 67,868 | 76,960 | 93,622 | 75,766 | |||
| TOTAL LIABILITIES AND EQUITY: | 108,525 | 366,344 | 364,696 | 374,906 | 395,595 | 393,339 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 37,985 | 27,715 | 29,675 | 22,258 | 31,470 | 33,511 | ||
| Cost of revenue | (26,021) | (3,387) | (3,065) | (3,234) | (13,923) | (11,005) | ||
| Cost of product and service sold | (3,387) | (3,065) | (3,234) | (11,005) | ||||
| Gross profit: | 11,964 | 24,328 | 26,610 | 19,024 | 17,547 | 22,506 | ||
| Operating expenses | (252,171) | (32,050) | (31,066) | (31,591) | (6,534) | (32,071) | ||
| Other undisclosed operating income (loss) | (7,118) | 5,203 | 824 | 1,091 | (10,746) | 4,576 | ||
| Operating income (loss): | (247,325) | (2,519) | (3,632) | (11,476) | 267 | (4,989) | ||
| Nonoperating income (expense) | (8,545) | (7,424) | (7,714) | (7,386) | 21,307 | (7,449) | ||
| Interest and debt expense | (58,633) | (7,984) | (7,773) | 27,100 | 49,643 | (7,465) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (314,503) | (17,927) | (19,119) | 8,238 | 71,217 | (19,903) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 58,633 | 7,984 | 7,773 | (27,100) | (49,643) | 7,465 | ||
| Income (loss) from continuing operations before income taxes: | (255,870) | (9,943) | (11,346) | (18,862) | 21,574 | (12,438) | ||
| Income tax expense (benefit) | 38,109 | 1,055 | 1,965 | 2,038 | (2,432) | (1,416) | ||
| Income (loss) from continuing operations: | (217,761) | (8,888) | (9,381) | (16,824) | 19,142 | (13,854) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | (13,854) | |
| Net income (loss) available to common stockholders, basic: | (217,761) | (8,888) | (9,381) | (16,824) | 19,142 | (13,854) | ||
| Other undisclosed net income available to common stockholders, diluted | 5,263 | |||||||
| Net income (loss) available to common stockholders, diluted: | (217,761) | (8,888) | (9,381) | (16,824) | 24,405 | (13,854) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (217,761) | (8,888) | (9,381) | (16,824) | 19,142 | (13,854) | ||
| Other comprehensive income (loss) | (163) | 161 | 91 | 1,352 | ||||
| Other undisclosed comprehensive income | 797 | 1,645 | ||||||
| Comprehensive income (loss): | (216,964) | (9,051) | (9,220) | (16,733) | 20,787 | (12,502) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (89) | (3,107) | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (217,053) | (9,051) | (9,220) | (16,733) | 17,680 | (12,502) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.